{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:25:00Z","timestamp":1761567900927,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cpet.2022.11.007","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T17:41:15Z","timestamp":1674668475000},"page":"243-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gastro-Entero-Pancreatic Tumors"],"prefix":"10.1016","volume":"18","author":[{"given":"Wajahat","family":"Khatri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ergi","family":"Spiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cpet.2022.11.007_bib1","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1245\/s10434-015-4471-x","article-title":"Octreoscan versus FDG-PET for neuroendocrine tumor staging: a biological approach","volume":"22","author":"Squires","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.cpet.2022.11.007_bib2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/cancers13081813","article-title":"Clinical utility of 18F-FDG pet in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis","volume":"13","author":"Alevroudis","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.007_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/a-1823-1275","article-title":"Personalisierte resektionsverfahren bei neuroendokrinen neoplasien des pankreas [Personalised surgical therapy for neuroendocrine neoplasia of the pancreas]","volume":"147","author":"B\u00f6sch","year":"2022","journal-title":"Zentralblatt f\u00fcr Chirurgie"},{"key":"10.1016\/j.cpet.2022.11.007_bib4","article-title":"Current best practice in the management of neuroendocrine tumors","volume":"10","author":"Tsoli","year":"2018","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.cpet.2022.11.007_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2022.11.007_bib6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jfma.2017.07.007","article-title":"68Ga-DOTATOC and 18F-FDG PET\/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: a prospective study in Taiwan","volume":"117","author":"Chen","year":"2018","journal-title":"J\u00a0Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.007_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.mednuc.2016.01.003","article-title":"The current role of 18F-FDOPA PET for neuroendocrine tumor imaging","volume":"40","author":"Lussey-Lepoutre","year":"2016","journal-title":"M\u00e9decine Nucl\u00e9aire"},{"issue":"17","key":"10.1016\/j.cpet.2022.11.007_bib8","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3748\/wjg.v28.i17.1768","article-title":"Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors","volume":"28","author":"Grey","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cpet.2022.11.007_bib9","first-page":"219","article-title":"Principles and application of molecular imaging for personalized medicine and guiding interventions in neuroendocrine tumors","author":"Hofman","year":"2016","journal-title":"Diagn Ther Nucl Med Neuroendocrine Tumors"},{"issue":"1","key":"10.1016\/j.cpet.2022.11.007_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2967\/jnumed.116.178095","article-title":"Comparison of the impact of 68 Ga-DOTATATE and 18F-FDG PET\/CT on clinical management in patients with neuroendocrine tumors","volume":"58","author":"Panagiotidis","year":"2016","journal-title":"J\u00a0Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2022.11.007_bib11","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.23469","article-title":"Functional imaging of neuroendocrine tumors with combined PET\/CT using 68 Ga-DOTATATE (DOTA-dphe1,tyr3-octreotate) and 18F-FDG","volume":"112","author":"Kayani","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.007_bib12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","author":"Binderup","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpet.2022.11.007_bib13","doi-asserted-by":"crossref","first-page":"109932","DOI":"10.1016\/j.ejrad.2021.109932","article-title":"Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)","volume":"143","author":"Papadakis","year":"2021","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.007_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.cpet.2022.11.007_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.cpet.2022.11.007_bib16","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2022.11.007_bib17","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2967\/jnumed.109.066639","article-title":"A\u00a0comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine tumors","volume":"50","author":"Kayani","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2022.11.007_bib18","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00259-016-3328-2","article-title":"Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET\/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle","volume":"43","author":"Nilica","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.cpet.2022.11.007_bib19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.cpet.2022.11.007_bib20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2967\/jnumed.117.206631","article-title":"SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: a proposed standardization framework","volume":"59","author":"Werner","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2022.11.007_bib21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00259-013-2369-z","article-title":"Role of 18FDG PET\/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours","volume":"40","author":"Severi","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.cpet.2022.11.007_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/RLU.0000000000004239","article-title":"Rechallenge with additional doses of 177Lu-DOTATOC after failure of maintenance therapy with cold somatostatin analogs","volume":"47","author":"Weich","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2022.11.007_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MNM.0000000000001350","article-title":"Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: systematic review and meta-analysis","volume":"42","author":"Kim","year":"2020","journal-title":"Nucl Med Commun"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.007_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/life11030198","article-title":"Long-term survival and value of 18F-FDG PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors treated with second peptide receptor radionuclide therapy course with 177Lu-DOTATATE","volume":"11","author":"Rodrigues","year":"2021","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.cpet.2022.11.007_bib25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12020-015-0661-3","article-title":"Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography","volume":"51","author":"Lapa","year":"2016","journal-title":"Endocrine"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859822000943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859822000943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:10:02Z","timestamp":1761563402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859822000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1556859822000943"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2022.11.007","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastro-Entero-Pancreatic Tumors","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2022.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}